Last reviewed · How we verify
acetylsalicyclic acid (ASA)
Acetylsalicylic acid (ASA) works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins and thromboxanes.
Acetylsalicylic acid (ASA) works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins and thromboxanes. Used for Prevention of cardiovascular thrombotic events in patients at risk of myocardial infarction or stroke, including those with a history of myocardial infarction, stroke, transient ischemic attack, or coronary artery bypass graft surgery, Relief of pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
At a glance
| Generic name | acetylsalicyclic acid (ASA) |
|---|---|
| Also known as | Aspirin |
| Sponsor | Sanofi |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | COX |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This inhibition leads to a decrease in the production of prostaglandins, which are mediators of inflammation and pain, and thromboxanes, which are involved in blood clotting. As a result, ASA has anti-inflammatory, analgesic, and antiplatelet effects.
Approved indications
- Prevention of cardiovascular thrombotic events in patients at risk of myocardial infarction or stroke, including those with a history of myocardial infarction, stroke, transient ischemic attack, or coronary artery bypass graft surgery
- Relief of pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis
Common side effects
- Gastrointestinal upset
- Hypersensitivity reactions
- Renal impairment
- Hemorrhage
Key clinical trials
- A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI) (PHASE3)
- Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease (PHASE3)
- Evaluate Analgesic Efficacy of Fast Release Aspirin (PHASE3)
- Evaluate Onset of Action of a Fast Release Aspirin (PHASE3)
- Aspirin Prophylaxis in Sickle Cell Disease (PHASE1)
- Ticagrelor in Human Endotoxemia Response to Human Endotoxemia (NA)
- Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A) (PHASE3)
- Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- acetylsalicyclic acid (ASA) CI brief — competitive landscape report
- acetylsalicyclic acid (ASA) updates RSS · CI watch RSS
- Sanofi portfolio CI